Article
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
EBioMedicine - 1 Sept 2020
Smeby Jørgen, Kryeziu Kushtrim, Berg Kaja C G, Eilertsen Ina A, Eide Peter W, Johannessen Bjarne, Guren Marianne G, Nesbakken Arild, Bruun Jarle, Lothe Ragnhild A, Sveen Anita
Abstract excerpt
BACKGROUND: PARP inhibitors are active in various tumour types beyond BRCA-mutant cancers, but their activity and molecular correlates in colorectal cancer (CRC) are not well studied. METHODS: Mutations and genome-wide mutational patterns associated with homologous recombination deficiency (HRD) were investigated in 255 primary CRCs with whole-exome sequencing and/or DNA copy number data. Efficacy of five PARP...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.